Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.
Low plasma erythropoietin (EPO) levels are a major factor in anemia of prematurity. Erythroid progenitors from neonates have responded well to EPO in vitro, (studies performed outside a living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback